Semaglutide Reduces Asthma Attacks in Diabetes: Expert Reaction

Real-World Data Links Semaglutide to Fewer Asthma and COPD Flare-Ups

Researchers evaluated between 20,000 and 22,000 patient records across four parallel studies to track acute respiratory attacks in individuals with asthma and chronic obstructive pulmonary disease. According to Professor Bloom, the data showed that patients prescribed GLP-1 therapies experienced fewer flare-ups than control groups taking other diabetes medications. The strongest association appeared with semaglutide use in asthma patients, alongside a reported 20 percent reduction in COPD flare-ups. Dr Bohee Lee presented the findings at the congress, highlighting that individuals with more pronounced asthma seemed to benefit the most from the treatment.

Scientific Caution: Association Versus Direct Causation

Independent experts emphasize that the findings establish an association rather than a direct causal relationship. Dr Marie Spreckley, a researcher on the prevention of diabetes at the University of Cambridge, noted that while the active-comparator design adjusted for factors like body mass index and smoking, observational health records cannot fully capture treatment adherence or individual clinical care differences. Professor Stephen Burgess, also from the University of Cambridge, cautioned that conference presentations lack the full detail of a peer-reviewed paper and that clinical trials remain necessary to confirm whether the drug actively prevents respiratory attacks.

Patient Guidance and Future Respiratory Trials

Medical professionals urge patients not to alter their medication regimens based on these preliminary findings. According to Professor Bloom, people with asthma or COPD should not start GLP-1 receptor agonists specifically for their lung condition outside of existing prescribing guidance. Dr Alexander Mathioudakis, chair of the European Respiratory Society’s group on airway pharmacology and treatment, stated that the study reinforces the need to incorporate metabolic health into respiratory care and include lung outcomes in future clinical trials. Dr Samantha Walker, director of research and innovation at Asthma + Lung UK, added that while the results offer a promising step for patients managing overlapping conditions, the data does not apply to individuals who lack diabetes or obesity co-morbidities.

Frequently Asked Questions

Does semaglutide cure asthma?

No. According to researchers, the study only identifies an association between semaglutide use and fewer asthma attacks in patients with type 2 diabetes. Clinical trials are required to prove causation.

Can patients without diabetes take semaglutide for lung health?

No. Experts emphasize that the current findings apply strictly to patients already eligible for GLP-1 treatments due to conditions like diabetes or obesity, and patients should not seek the drug solely for respiratory management.

What dosage showed the strongest results?

Researchers noted that the connection to reduced flare-ups was stronger among patients receiving higher doses of semaglutide, though experts advise interpreting dose-response estimates cautiously until further trials are completed.